Meet our experts at the @vaccinenation World Vaccine Congress Washington on 31 Mar–2 Apr, at the Walter E. Washington Convention Center in Washington, DC. As a purpose-built CRO, we operate as one aligned, agile team across every stage of development, from early (pre)-clinical through to later phase studies. With direct access to scientific resources, specialist laboratories, and a 50 bed quarantine unit with on-site labs, we move quickly, efficiently, and with uncompromising quality. Guided by scientific and technical leadership, ethical integrity, and collaborative partnerships, we work across a diverse global community to accelerate vaccine development and infectious disease research — delivering measurable results that make a lasting difference. 📍 Meet our hVIVO experts at Booth 249 🎤 Presentation: RSV‑hMPV‑PIV combination vaccine efficacy testing platform on Wed 1 Apr, 2:40pm Learn more: hvivo.com/world-vaccine-cong… #ClinicalTrials #InfectiousDisease #VaccineDevelopment #ScientificLeadership #HumanChallengeModel

Catch up with Chief Scientific Officer Dr Andrew Catchpole our on-demand webinar on the world’s first RSV-B Human Challenge Model, developed at hVIVO. The webinar shares our world-leading expertise and insight into RSV virus isolation, GMP manufacturing, and the robust clinical data supporting vaccine and antiviral development. By watching the recording, you’ll gain a comprehensive understanding of our end-to-end human challenge trial services, proven patient recruitment approach, and specialist laboratory capabilities, alongside insights into RSV-hMPV-PIV trivalent challenge platform readiness and key comparative data on RSV-B versus RSV-A infection dynamics and incidence rates. 📍 Heading to RESVINET? Schedule a meeting with our team or look out for hVIVO onsite to discuss how our RSV-B and broader challenge models can support your development programmes. 🎥 Watch the full webinar recording: hvivo.com/rsv-b-webinar/?utm… 📩 bd@hvivo.com #RSV #RSVB #HumanChallengeModel #CHIM #VaccineDevelopment #AntiviralResearch #RespiratoryVirus #ClinicalTrials #RESVINET

“The industry is really waking up to the value of human challenge models” Mo Khan, of @hVIVO_UK #HVO talks to Vox about the company’s latest contract win, a £13.1m deal to develop a #humanchallengemodel for #Influenza B 🔗Click here to watch: youtube.com/watch?v=4Qx1kLod…

“The industry is really waking up to the value of human challenge models” Mo Khan, of @hVIVO_UK #HVO talks to Vox about the company’s latest contract win, a £13.1m deal to develop a #humanchallengemodel for #Influenza B 🔗Click here to watch: voxmarkets.co.uk/articles/q-…

MCRI clinician-scientist @JoshOsowicki tells us how he is using his @NHMRC Investigator Grant to advance Australian human challenge trials for priority pathogens. Watch here: vimeo.com/622874878 @nhmrc_grants #humanchallengemodel #strepa #tropicaldisease

Open Orphan subsidiary develops human study for malaria - is.gd/WrEUAm - #ORPH @OpenOrphan #Vaccines #Antivirals #hVIVO #VennLifeSciences #HumanChallengeModel #Malaria #DirectorsTalkInterviews